Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Soria, Jean Charles; Felip, Enriqueta; Cobo, Manuel; Lü, Shun; Syrigos, Konstantinos; Lee, Ki Hyeong; Göker, Erdem; Georgoulias, Vassilis; Li, Wei; Isla, Dolores; Güçlü, Salih Zeki; Morabito, Alessandro; Min, Young Joo; Ardizzoni, Andrea; Gadgeel, Shirish M.; Wang, Bushi; Chand, Vikram K.; Goss, Glenwood D.

doi:10.1016/s1470-2045(15)00006-6

Cited by 378 publications

(360 citation statements)

References 38 publications

Supporting

Mentioning

342

Contrasting

Unclassified

Order By: Relevance

“…Based on article identification and selection, we totally included 28 trials from 35 articles (9-30), involving 17,466 randomly assigned patients ( Figure 1) (31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43).…”

Section: Trial Searching and Characteristicsmentioning

confidence: 99%

Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years

Zhang¹,

Zhang²,

Tang³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

Section: Trial Searching and Characteristicsmentioning

confidence: 99%

Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years

Zhang¹,

Zhang²,

Tang³

et al. 2017

Ann. Transl. Med.

View full text Add to dashboard Cite

“…However, several new second-line options have recently been developed in this setting, including the anti-vascular endothelial growth factor receptor-2 antibody, ramucirumab (combined with docetaxel) [1]; the immune checkpoint inhibitors, nivolumab [2], pembrolizumab [3] and atezolizumab [4]; and the ErbB family blocker, afatinib [5]. This rapid expansion of treatment options has inevitably led to questions regarding optimal treatment choice and sequence.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…Тяжесть нежела-тельных явлений также была схожей в обеих группах (количество пациентов, имевших нежелательные явления не менее чем 3 степени тяжести, составило 57% против 57% соответственно). Нежелательные явления 3 степени тяжести, связанные с лекарственным препаратом, были выявлены у 25% пациентов группы афатиниба и 16% пациентов группы эрлотиниба [71].…”

Section: заключениеunclassified

Algorithms for Management of Patients With Adverse Events on Therapy With Tyrosine Kinase Inhibitors Egfr

Сакаева¹

2017

Med. sov.

View full text Add to dashboard Cite

С емейство рецепторов ErbB является одной из наиболее широко изученных систем передачи сигналов [1]. Семейство ErbB включает четыре мембранно-связанных структурно родственных рецепто-ра тирозинкиназы: рецептор EGF (EGFR; также известен как ErbB1), HER2 (ErbB2), ErbB3 и ErbB4 [2]. Путь ErbB является одной из наиболее широко изученных систем передачи сигналов, вовлеченных в функционирование нормальных клеток, и при некоторых типах рака [1]. Нарушение регуляции активности рецепторов семейства ErbB и нисходящих сигнальных путей связано с развити-ем некоторых опухолей у человека.Механизм активации передачи сигналов ErbB зависит от лиганд-индуцированной стабильности гомо-или гете-родимеров, образованных различными тирозинкиназами рецепторов семейства ErbB [3]. Рецепторы семейства ErbB являются клинически доказанными мишенями для новых противоопухолевых препаратов [4][5][6][7].Ингибиторы EGFR показаны для лечения колорек-тального рака (панитумумаб, цетуксимаб), немелкокле-точного рака легкого (гефитиниб, эрлотиниб, афатиниб), плоскоклеточного рака головы и шеи (цетуксимаб), рака поджелудочной железы (эрлотиниб).В отличие от цитотоксической химиотерапии, лечение ингибиторами EGFR сопровождается минимальными неспеци фическими и гематологическими побочными эффектами.Активирующие мутации гена рецептора EGFR явля-ются наиболее значимыми предикторами ответа на ингибиторы тирозинкиназы EGFR (ИТК-EGFR) гефити- Ключевые слова: местнораспространенный и метастатический немелкоклеточный рак легкого, ингибиторы тирозин-киназы EGFR, терапия, нежелательные явления. D.D. SAKAEVA, MD, Prof., Republican Oncologic Dispensary of the Ministry of Health of the Republic of Bashkortostan, Ufa ALGORITHMS FOR MANAGEMENT OF PATIENTS WITH ADVERSE EVENTS ON THERAPY WITH TYROSINE KINASE INHIBITORS EGFRThe tyrosine kinase inhibitors (TKIs) of the epidermal receptor growth factor (EGFR) such as gefitinib, erlotinib and afatinib, are the standard first-line therapy in locally advanced and metastatic non-small cell lung cancer (NSCLC) with frequent mutations of the EGFR gene. These drugs are more effective from the point of view of frequency response (FR) and survival without progression (SWP), less toxic and better tolerated than the standard two-component chemotherapy based on platinum drugs. The most frequent adverse events (AE) are gastrointestinal (GI) (diarrhea and stomatitis/mucositis) and dermatological (rash, dry skin and paronychia). They are usually mild, but in some cases symptoms can be moderate and more severity and have a negative impact on quality of life (QOL) of the patient and can require dose adjustment or discontinuation of treatment. Management of AEs, including preventive measures, supportive therapy, temporary cancellation and a reduction in the dose of the drug is important. Recommendations for the prevention and treatment of dermatological toxicity (rash, dry skin and paronychia) and toxicity for the gastrointestinal tract (diarrhoea, stomatitis and mucositis) related to therapy TKI-EGFR are developed. These guidelines descri...

show abstract

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Cited by 378 publications

References 38 publications

Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years

Evaluation bias in objective response rate and disease control rate between blinded independent central review and local assessment: a study-level pooled analysis of phase III randomized control trials in the past seven years

Evaluation of the VeriStrat ® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study

Algorithms for Management of Patients With Adverse Events on Therapy With Tyrosine Kinase Inhibitors Egfr

Contact Info

Product

Resources

About